Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
48.66
-0.09 (-0.18%)
At close: Sep 15, 2025, 4:00 PM EDT
48.60
-0.06 (-0.12%)
After-hours: Sep 15, 2025, 5:59 PM EDT

Bright Minds Biosciences Cash Flow Statement

Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Jun '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2019
Net Income
-8.92-2.8-7.37-14.96-8.65-0.48
Upgrade
Depreciation & Amortization
0.130.070.070.01--
Upgrade
Asset Writedown & Restructuring Costs
---0--
Upgrade
Stock-Based Compensation
2.320.841.150.90.880.16
Upgrade
Other Operating Activities
-0.88-00.07-0.260.14-
Upgrade
Change in Accounts Payable
0.360.24-1.20.770.510.11
Upgrade
Change in Other Net Operating Assets
-0.91-0.20.26-0.04-0.2-0.08
Upgrade
Operating Cash Flow
-7.89-1.85-7.02-13.59-7.32-0.29
Upgrade
Long-Term Debt Repaid
--0.09-0.09-0.01--
Upgrade
Net Debt Issued (Repaid)
-0.1-0.09-0.09-0.01--
Upgrade
Issuance of Common Stock
49.820.91.47627.841.01
Upgrade
Other Financing Activities
2.5100.8-0.8-1.79-
Upgrade
Financing Cash Flow
52.230.812.195.226.061.01
Upgrade
Foreign Exchange Rate Adjustments
0.860.01-0.050.260.22-
Upgrade
Net Cash Flow
45.2-1.03-4.88-8.1318.960.72
Upgrade
Levered Free Cash Flow
-3.46-0.69-4.22-7.58-3.85-0.1
Upgrade
Unlevered Free Cash Flow
-3.46-0.68-4.22-7.58-3.85-0.1
Upgrade
Change in Working Capital
-0.540.04-0.940.720.310.03
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q